Hepatitis - Pathophysiology

SECTION 1

Historical Context & Discovery of Hepatitis

The recognition of hepatitis as a clinical entity has ancient roots, with descriptions of epidemic jaundice appearing in Babylonian and Hippocratic texts dating back millennia. For centuries, clinicians observed that certain populations experienced outbreaks of jaundice—yellowing of the skin and sclera—particularly during wartime and in crowded urban environments, though the underlying etiology remained elusive. The modern understanding of hepatitis began to crystallize in the early twentieth century as investigators distinguished between infectious and serum-borne forms of the disease, laying the groundwork for the identification of specific viral agents. Today, hepatitis is recognized as a multifactorial condition with viral, autoimmune, toxic, and metabolic etiologies, each producing characteristic patterns of hepatocellular injury and inflammatory response.

1885 • Lürman's Observation of Serum Hepatitis

Following a smallpox vaccination campaign in Bremen shipyard workers, A. Lürman documented an outbreak of jaundice among vaccinated individuals who had received human lymph-derived vaccine, providing the first epidemiological evidence for a blood-borne hepatotropic agent.

1947 • MacCallum's A/B Classification

F.O. MacCallum proposed the classification of hepatitis A (infectious, fecal-oral) and hepatitis B (serum, parenteral), establishing a framework that guided research for decades.

1965 • Discovery of the Australia Antigen (HBsAg)

Baruch Blumberg identified the Australia antigen in the serum of an Aboriginal Australian, later recognized as the hepatitis B surface antigen. This discovery earned Blumberg the 1976 Nobel Prize and enabled development of serologic screening.

1989 • Identification of Hepatitis C Virus

Michael Houghton and colleagues at Chiron Corporation cloned the genome of hepatitis C virus (HCV), resolving the mystery of 'non-A, non-B hepatitis' and paving the way for blood supply screening and antiviral therapy development.

2013–Present • Direct-Acting Antivirals (DAAs) Revolutionize HCV Treatment

The introduction of sofosbuvir and subsequent combination DAA regimens achieved sustained virologic response rates exceeding 95%, transforming HCV from a chronic, often progressive disease into a curable condition and raising the prospect of global elimination.

The historical trajectory of hepatitis reveals a central question in hepatobiliary pathophysiology: how do diverse injurious agents converge on common pathways of hepatocellular damage, inflammation, and fibrosis? Understanding the answer requires an integrated knowledge of liver histology, innate and adaptive immune mechanisms, viral replication strategies, and the molecular cascades that bridge acute injury and chronic disease progression.

SECTION 2

Core Principles & Definitions

At its foundation, hepatitis refers to inflammation of the hepatic parenchyma, characterized by hepatocyte injury, immune cell infiltration, and variable degrees of necrosis. The clinical and histological manifestations depend on the nature, intensity, and duration of the insult. Whether triggered by viral replication within hepatocytes, autoimmune targeting of hepatic antigens, or direct toxin-mediated cell death, the liver's response follows recognizable pathophysiological patterns that can be organized into several foundational principles.

Hepatocellular Injury

Hepatocyte damage is the initiating event, occurring through cytopathic viral effects, immune-mediated cytotoxicity (CD8⁺ T cells, NK cells), or direct toxin exposure. Injured hepatocytes release damage-associated molecular patterns (DAMPs) and intracellular enzymes (ALT, AST) into the circulation.

Inflammatory Response

DAMPs activate resident Kupffer cells (hepatic macrophages) and hepatic stellate cells, prompting cytokine release (TNF-α, IL-1β, IL-6) and recruitment of neutrophils, monocytes, and lymphocytes to the portal and lobular regions.

Acute vs. Chronic Distinction

Acute hepatitis resolves within six months and may be subclinical or fulminant. Chronic hepatitis persists beyond six months, driven by ongoing immune activation and impaired viral clearance, leading to progressive fibrosis.

Fibrosis–Cirrhosis Continuum

Persistent hepatocyte death triggers activation of hepatic stellate cells, which transdifferentiate into myofibroblasts and deposit collagen in the space of Disse. Progressive fibrosis distorts the hepatic architecture, culminating in cirrhosis with regenerative nodules and portal hypertension.

Cholestasis & Impaired Function

Hepatocyte swelling and inflammation compress intrahepatic bile canaliculi, causing intrahepatic cholestasis with conjugated hyperbilirubinemia. Impaired synthetic function manifests as decreased albumin, clotting factor deficiency, and reduced drug metabolism.

✦

KEY TAKEAWAY

Think of the liver as a factory with multiple assembly lines (metabolic, synthetic, detoxification). Hepatitis is like a fire breaking out on the factory floor—regardless of whether the fire was caused by an electrical fault (virus), a chemical spill (toxin), or sabotage (autoimmunity), the damage disrupts production, triggers the alarm system (immune response), and if the fire isn't contained, the factory undergoes reconstruction with scar tissue (fibrosis) that progressively replaces functional machinery. Understanding this common pathway is key: injury → inflammation → regeneration/fibrosis is the universal language of hepatic pathophysiology.

SECTION 3

Visual Explanation: Liver Lobule Under Attack

The left panel depicts a normal hepatic lobule with orderly hepatocyte cords (gold rectangles) radiating from the central vein (CV) toward the portal triads (PT), separated by sinusoidal channels (dashed purple lines). The right panel illustrates the hepatitis lobule: necrotic hepatocytes (red, marked ✕), infiltrating lymphocytes (L, cyan) and activated Kupffer cells (K, pink), and early collagen deposition (orange lines) in the periportal and pericentral zones.

The diagram above captures the key histological transition that defines hepatitis. In the normal lobule, blood flows from the portal triad through the sinusoids to the central vein, bathing orderly hepatocyte plates that perform metabolic and synthetic functions. During hepatitis, the pattern of inflammatory infiltrate distribution carries diagnostic significance: viral hepatitis typically shows lobular and portal inflammation with lymphocytic predominance, whereas autoimmune hepatitis often features interface hepatitis (formerly 'piecemeal necrosis') at the limiting plate where the portal tract meets the hepatic parenchyma. The zone-specific patterns of hepatocyte necrosis—zone 3 (centrilobular) in acetaminophen toxicity, zone 1 (periportal) in phosphorus poisoning—reflect the metabolic gradients across the lobule, including oxygen tension and cytochrome P450 enzyme concentration.

SECTION 4

Pathogenic Mechanisms of Hepatocellular Injury

The mechanisms by which hepatitis develops vary considerably by etiology, yet they converge on shared downstream pathways of cell death, immune activation, and tissue remodeling. Understanding these mechanisms requires integrating virology, immunology, and cellular biology. Below, we examine the major mechanistic categories in detail.

Immune-Mediated Hepatocyte Killing (Viral Hepatitis)

Most hepatotropic viruses are not directly cytopathic in the traditional sense; rather, the liver damage in hepatitis B is predominantly immune-mediated. When HBV infects hepatocytes, viral antigens (HBcAg, HBeAg) are processed and presented on the cell surface via MHC class I molecules. Virus-specific CD8⁺ cytotoxic T lymphocytes (CTLs) recognize these antigen-MHC complexes and kill infected hepatocytes through perforin-granzyme and Fas-FasL pathways. The vigor of the CTL response is paradoxically double-edged: a robust response clears the virus but inflicts substantial hepatocellular damage (acute hepatitis), while an inadequate response fails to clear the virus, leading to chronic infection with smoldering inflammation. This immunological paradox explains why immunosuppressed individuals (e.g., neonates, organ transplant recipients) infected with HBV rarely develop acute symptomatic hepatitis but have very high rates of chronicity.

Direct Cytopathic Effects

Hepatitis A virus (HAV) and hepatitis D virus (HDV, delta agent) can exert direct cytopathic effects on hepatocytes, although immune-mediated injury still plays a contributory role. In alcoholic hepatitis, acetaldehyde—the primary metabolite of ethanol generated by alcohol dehydrogenase and CYP2E1—forms protein adducts that induce oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum stress, triggering both apoptosis and necrosis. Non-alcoholic steatohepatitis (NASH) involves a 'two-hit' or 'multiple parallel hits' model wherein hepatic steatosis sensitizes hepatocytes to secondary insults including lipid peroxidation, proinflammatory cytokines from adipose tissue, and gut-derived endotoxin.

Autoimmune Mechanisms

In autoimmune hepatitis (AIH), loss of immune tolerance to hepatocyte self-antigens results in T-cell–mediated destruction of the hepatic parenchyma. Molecular mimicry—whereby viral or environmental antigens share epitopes with hepatocyte surface proteins—is one proposed trigger. AIH is characterized by hypergammaglobulinemia, the presence of autoantibodies (ANA, anti-smooth muscle antibody, anti-LKM-1), and a dramatic response to immunosuppressive therapy, confirming the autoimmune basis of the disease.

This flowchart demonstrates the convergent pathway model of hepatitis. Diverse etiologies (viral, toxic, autoimmune, metabolic) all produce hepatocyte injury, releasing DAMPs that activate Kupffer cells and stellate cells, ultimately driving the shared endpoints of chronic inflammation and fibrosis.

ℹ

Clinical Correlation

The pattern of liver enzyme elevation helps differentiate the mechanism of injury. A hepatocellular pattern (ALT >> ALP, with R ratio > 5) indicates hepatocyte necrosis, typical of viral and autoimmune hepatitis. A cholestatic pattern (ALP >> ALT, R ratio < 2) suggests biliary obstruction or drug-induced cholestasis. A mixed pattern (R ratio 2–5) occurs in drug-induced liver injury (DILI) and certain viral hepatitides.

SECTION 5

Classification of Hepatitis Viruses

Five major hepatotropic viruses (A through E) cause the overwhelming majority of viral hepatitis worldwide. Though they share a tropism for the liver, these agents differ dramatically in their genomic structure, transmission route, propensity for chronicity, and clinical significance. A thorough understanding of these distinctions is essential for clinical reasoning, as the serologic workup, disease course, and management strategy differ for each virus.

Feature	HAV	HBV	HCV	HDV	HEV
Genome	ssRNA (+)	dsDNA (partial)	ssRNA (+)	ssRNA (−), circular	ssRNA (+)
Family	Picornaviridae	Hepadnaviridae	Flaviviridae	Deltaviridae (defective)	Hepeviridae
Transmission	Fecal-oral	Parenteral, sexual, vertical	Parenteral (primarily)	Parenteral (requires HBV)	Fecal-oral (waterborne)
Incubation	2–6 weeks	1–6 months	2 weeks–6 months	Superinfection: 4–7 wk	2–6 weeks
Chronicity	Never	~5% adults; ~90% neonates	~75–85%	~5% co-inf; ~80% super-inf	Rare (immunosupp.)
HCC Risk	No	Yes (even without cirrhosis)	Yes (via cirrhosis)	Accelerates HBV-related HCC	No
Vaccine	Yes (inactivated)	Yes (recombinant HBsAg)	No	HBV vaccine protects	Approved in China
Key Serologic Marker	Anti-HAV IgM (acute)	HBsAg, anti-HBc, HBeAg	Anti-HCV, HCV RNA	Anti-HDV, HDV RNA	Anti-HEV IgM

Comparison of the five major hepatitis viruses

⚠

High-Yield Distinction

HDV is a defective satellite virus that requires HBsAg for virion assembly and cannot replicate independently. Co-infection (simultaneous HBV + HDV) usually resolves, while superinfection (HDV in a chronic HBV carrier) typically leads to severe chronic hepatitis with accelerated progression to cirrhosis.

The distinction between fecal-oral (HAV, HEV) and parenteral (HBV, HCV, HDV) transmission routes has profound public health implications. Fecal-oral agents cause self-limited acute infections (with the notable exception of HEV genotype 3/4 in immunocompromised patients) and are effectively controlled by sanitation and vaccination. Parenteral agents, particularly HBV and HCV, carry the risk of chronic infection, cirrhosis, and hepatocellular carcinoma (HCC), making them leading indications for liver transplantation worldwide. HBV is unique among the DNA viruses for its use of a reverse transcriptase step, generating covalently closed circular DNA (cccDNA) that persists in the hepatocyte nucleus as a stable episome—this explains why chronic HBV is controlled but not truly eradicated by current nucleos(t)ide analogues.

SECTION 6

Worked Example: Interpreting Hepatitis B Serologies

Interpreting the hepatitis B serologic panel is a critical clinical skill. The following worked example walks through the systematic approach to a patient with suspected HBV infection.

Case: 28-Year-Old with Jaundice and Fatigue

1
Step 1 — Gather Clinical Data

A 28-year-old healthcare worker presents with 3 weeks of progressive fatigue, right upper quadrant discomfort, dark urine, and scleral icterus. Lab results: ALT 1,200 U/L, AST 980 U/L, total bilirubin 8.2 mg/dL (conjugated 6.1 mg/dL), alkaline phosphatase 145 U/L. The R ratio is calculated as (ALT/ULN ALT) ÷ (ALP/ULN ALP) = (1200/40) ÷ (145/120) = 30 ÷ 1.21 ≈ 24.8, indicating a hepatocellular pattern of injury.

R ratio ≈ 24.8 → hepatocellular injury pattern
2
Step 2 — Evaluate the Hepatitis B Panel

Serologic results: HBsAg (+), anti-HBs (−), anti-HBc total (+), anti-HBc IgM (+), HBeAg (+), anti-HBe (−). Begin interpretation systematically. HBsAg positive confirms active HBV infection (either acute or chronic). Anti-HBc IgM positive distinguishes acute from chronic infection—IgM anti-HBc is the hallmark of acute HBV hepatitis.

HBsAg (+) and IgM anti-HBc (+) → Acute HBV infection
3
Step 3 — Assess Viral Replication Status

HBeAg positive indicates high levels of viral replication and high infectivity. In acute infection, HBeAg positivity is expected during the early, highly replicative phase. Anti-HBe negativity is consistent—seroconversion from HBeAg to anti-HBe occurs later during immune clearance. This patient is in the immune-active phase of acute HBV infection, explaining the high transaminases.

HBeAg (+) → High viral replication, high infectivity
4
Step 4 — Determine Immunity Status

Anti-HBs negative confirms the patient has not yet cleared the virus (anti-HBs is a marker of immunity, either from resolved infection or vaccination). In most immunocompetent adults, acute HBV infection will resolve spontaneously in >95% of cases, with eventual disappearance of HBsAg and appearance of anti-HBs. However, the patient should be monitored for progression to chronicity (HBsAg persistence >6 months).

Anti-HBs (−) → No immunity yet; monitor for clearance vs. chronicity
5
Step 5 — Synthesize and Plan

Diagnosis: Acute hepatitis B infection in a young, immunocompetent adult. Management is primarily supportive (hydration, avoidance of hepatotoxins, monitoring for fulminant hepatic failure). Antiviral therapy is generally reserved for severe or protracted acute cases. Contacts should be offered HBV vaccination and hepatitis B immunoglobulin (HBIG) as post-exposure prophylaxis. Serial serologies at 6 months will confirm resolution (HBsAg clearance, anti-HBs seroconversion) or diagnose chronic HBV.

Acute HBV → Supportive care, contact prophylaxis, 6-month follow-up serologies

SECTION 7

Acute vs. Chronic Hepatitis: Comparative Analysis

The transition from acute to chronic hepatitis is one of the most clinically significant events in hepatology, and the distinction carries major implications for patient management, prognosis, and public health strategy. While both forms share the common denominator of hepatocellular inflammation, they diverge in pathophysiology, histological appearance, laboratory patterns, and outcomes.

Feature	Acute Hepatitis	Chronic Hepatitis
Duration	< 6 months	≥ 6 months
Transaminases	Markedly elevated (often >10× ULN); ALT > AST	Mildly to moderately elevated (1–5× ULN); AST > ALT in cirrhosis
Histology	Lobular inflammation, hepatocyte ballooning, spotty necrosis, apoptotic bodies (Councilman bodies)	Portal/periportal inflammation, interface hepatitis, progressive fibrosis, ground-glass hepatocytes (HBV)
Immune Response	Vigorous CTL response; effective viral clearance (in most cases)	Inadequate/exhausted CTL response; viral persistence, T-cell exhaustion (PD-1 upregulation)
Complications	Fulminant hepatic failure (rare, <1% for HBV); complete recovery in most	Cirrhosis, portal hypertension, HCC, liver failure
Treatment Goal	Supportive care; prevent transmission	Viral suppression/cure; halt fibrosis progression; HCC surveillance

Acute vs. Chronic Hepatitis: Key Distinguishing Features

💡

CLINICAL PEARL

The AST:ALT ratio (De Ritis ratio) provides a diagnostic clue within chronic liver disease. An AST:ALT ratio > 2 strongly suggests alcoholic liver disease, because alcohol induces mitochondrial injury (releasing mitochondrial AST) and depletes pyridoxal phosphate (the cofactor for ALT synthesis). In viral hepatitis without cirrhosis, ALT typically exceeds AST. However, as fibrosis advances to cirrhosis from any cause, the ratio inverts (AST > ALT) because reduced hepatocyte mass decreases ALT production while sinusoidal capillarization impairs AST clearance.

SECTION 8

Connection to Advanced Theory: Fibrogenesis and Hepatocellular Carcinoma

Chronic hepatitis, regardless of etiology, feeds into two advanced pathophysiological processes that represent the most feared consequences of persistent hepatic inflammation: progressive hepatic fibrogenesis and hepatocarcinogenesis. Understanding these processes at the molecular level connects the foundational concepts of hepatitis to the frontiers of hepatology research.

Concept	Foundational (This Lesson)	Advanced Extension
Fibrosis	Stellate cell activation → collagen deposition in space of Disse → bridging fibrosis → cirrhosis	TGF-β/SMAD signaling cascade; PDGF-driven stellate cell proliferation; matrix metalloproteinase (MMP) / TIMP imbalance; reversibility of early fibrosis with etiologic treatment
Portal Hypertension	Distorted hepatic architecture increases sinusoidal resistance → portal pressure rise	Hepatic venous pressure gradient (HVPG); clinically significant portal HTN at ≥10 mmHg; splanchnic vasodilation and hyperdynamic circulation; variceal hemorrhage
Hepatocarcinogenesis	Chronic inflammation → dysplasia → HCC; HBV integrates DNA directly	HBV X protein (HBx) inactivates p53 and activates Wnt/β-catenin; HCV NS5A protein inhibits apoptosis; telomere shortening in cirrhotic regenerative nodules; epigenetic alterations; AFP and LIRADS surveillance
Immune Exhaustion	Inadequate CTL response allows viral persistence	PD-1/PD-L1, CTLA-4 checkpoint upregulation on virus-specific T cells; therapeutic immune checkpoint inhibitors (nivolumab for HCC); regulatory T-cell expansion in chronic HBV

From Foundational Hepatitis Concepts to Advanced Hepatology

The recognition that hepatic fibrosis is potentially reversible with effective etiologic treatment represents one of the most transformative insights in modern hepatology. Studies of patients cured of HCV with direct-acting antivirals have demonstrated regression of advanced fibrosis and even early cirrhosis, as clearance of the inflammatory stimulus allows matrix metalloproteinases to degrade excess collagen. Similarly, antiviral suppression of HBV with entecavir or tenofovir has shown histological improvement over years of treatment. These findings underscore the importance of early diagnosis and treatment of hepatitis: the pathophysiological cascade is not a one-way street, and the liver retains remarkable regenerative capacity when given the opportunity.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why neonates infected with hepatitis B virus at birth have a >90% rate of developing chronic HBV infection, whereas immunocompetent adults infected as adults have a <5% chronicity rate. What does this tell you about the role of the immune response in both viral clearance and liver damage?

Show answer

The neonatal immune system is immature and exhibits immune tolerance to antigens encountered in early life, including HBV antigens. The neonate's CD8⁺ CTL response to infected hepatocytes is insufficient to clear the virus, resulting in viral persistence and establishment of chronic infection. In contrast, immunocompetent adults mount a vigorous, multispecific CTL response against HBV-infected hepatocytes, which clears the virus but simultaneously causes the hepatocellular damage manifesting as acute hepatitis. This illustrates the immunological paradox of HBV: the same immune response responsible for liver injury is also required for viral clearance. A weak immune response causes less acute damage but permits chronicity, while a strong response causes more acute hepatocyte destruction but achieves viral elimination.

Question 2: BASIC CALCULATION

A patient's lab results show ALT = 850 U/L (ULN = 40 U/L) and ALP = 110 U/L (ULN = 120 U/L). Calculate the R ratio and classify the pattern of liver injury.

Show answer

The R ratio (also called the R value) is calculated as: R = (ALT ÷ ULN of ALT) ÷ (ALP ÷ ULN of ALP) = (850 ÷ 40) ÷ (110 ÷ 120) = 21.25 ÷ 0.917 ≈ 23.2. An R ratio > 5 indicates a hepatocellular pattern of injury, which is consistent with acute viral hepatitis, autoimmune hepatitis, or drug-induced hepatocellular injury. An R ratio < 2 indicates a cholestatic pattern, and 2–5 indicates a mixed pattern. This patient's R ratio of approximately 23.2 strongly suggests hepatocellular injury, and the marked ALT elevation (>20× ULN) is characteristic of acute viral hepatitis or acetaminophen toxicity.

Question 3: INTERMEDIATE

A 45-year-old patient who is a known chronic hepatitis B carrier presents with acute worsening of liver function. Serologies reveal: HBsAg (+), anti-HBc IgM (−), anti-HDV IgM (+), HDV RNA (+). Explain the serologic findings and predict the expected clinical course, comparing this scenario with HBV/HDV co-infection.

Show answer

This patient has HDV superinfection on a background of chronic HBV infection. The key evidence is: (1) HBsAg positive confirms ongoing HBV infection; (2) anti-HBc IgM negative rules out acute HBV—this is chronic HBV; (3) anti-HDV IgM positive with detectable HDV RNA confirms acute HDV superinfection. HDV is a defective satellite virus requiring HBsAg for virion assembly, so it can only infect individuals with existing HBV. In superinfection (HDV acquired by a chronic HBV carrier), approximately 80% of patients develop chronic HDV, leading to accelerated fibrosis progression and higher rates of decompensated cirrhosis compared to HBV monoinfection. This contrasts with co-infection (simultaneous acute HBV + HDV acquisition), which typically resolves in ~95% of cases because the host clears HBV, thereby eliminating HDV's dependence on HBsAg.

Question 4: APPLIED

A 52-year-old woman with a history of intravenous drug use 30 years ago is found to have chronic hepatitis C (genotype 1a) with a FIB-4 score of 4.8 and liver biopsy showing bridging fibrosis (METAVIR F3). She is treated with a direct-acting antiviral (DAA) regimen and achieves sustained virologic response (SVR). Discuss (a) whether she still requires HCC surveillance post-SVR, (b) the pathophysiological rationale for fibrosis regression, and (c) any residual risks.

Show answer

(a) Yes, she should continue HCC surveillance. Guidelines recommend biannual ultrasound ± AFP for patients with advanced fibrosis (F3) or cirrhosis, even after achieving SVR, because the risk of HCC, although substantially reduced, remains elevated compared to the general population. Cumulative epigenetic changes and telomere shortening in hepatocytes with advanced fibrosis create an oncogenic substrate that persists even after viral eradication. (b) Fibrosis regression following SVR is mediated by the removal of the chronic inflammatory stimulus, which allows hepatic stellate cells to undergo apoptosis or revert to a quiescent phenotype. Matrix metalloproteinases (MMPs), no longer counterbalanced by tissue inhibitors of metalloproteinases (TIMPs) produced by active stellate cells, degrade accumulated extracellular collagen. Studies have documented regression from F3 to F1 or F0 in some patients within 3–5 years. (c) Residual risks include the persistent HCC risk discussed above, potential reinfection with HCV if ongoing risk behaviors continue (DAA-induced SVR does not confer protective immunity), and portal hypertensive complications if significant architectural distortion is already present.

Question 5: CRITICAL THINKING

Hepatitis B virus can cause hepatocellular carcinoma even in the absence of cirrhosis, while hepatitis C virus–associated HCC almost always arises in the context of cirrhosis. Propose a molecular explanation for this difference, referencing specific viral proteins and their interactions with tumor suppressor pathways.

Show answer

The fundamental difference lies in the mechanisms of oncogenesis employed by each virus. HBV is a DNA virus whose genome can integrate into the host hepatocyte chromosomal DNA, a process that can occur early in infection and independently of fibrosis. Integration may directly disrupt tumor suppressor genes or activate proto-oncogenes through insertional mutagenesis. Additionally, the HBV X protein (HBx) is a multifunctional transactivator that inactivates p53 (the 'guardian of the genome'), activates the Wnt/β-catenin proliferative signaling pathway, stimulates NF-κB–mediated survival signals, and promotes epigenetic modifications including DNA methylation of tumor suppressor gene promoters. These direct oncogenic mechanisms explain why HCC can develop in non-cirrhotic HBV carriers. In contrast, HCV is an RNA virus that does not integrate into the host genome. Its oncogenic potential is primarily indirect, operating through decades of chronic necro-inflammation that drives compensatory hepatocyte proliferation in a microenvironment of oxidative stress, chromosomal instability, and telomere erosion. While HCV NS5A and core proteins have been shown to inhibit apoptosis and modulate cell signaling in vitro, these effects appear insufficient for carcinogenesis without the 'fertile soil' of cirrhotic liver remodeling. This distinction has clinical implications: HCC screening should begin at diagnosis for chronic HBV carriers (especially those with family history, high viral load, or African ancestry), whereas for HCV, screening is initiated when cirrhosis develops.

SUMMARY

Hepatitis — Key Concepts Review

Summary

Hepatitis is defined as inflammation of the hepatic parenchyma resulting from viral, autoimmune, toxic, or metabolic insults. Regardless of etiology, the pathophysiological cascade follows a convergent pathway: hepatocyte injury releases DAMPs that activate Kupffer cells and recruit inflammatory cells, while persistent injury triggers hepatic stellate cell activation with collagen deposition in the space of Disse, driving the fibrosis–cirrhosis continuum. The five major hepatitis viruses (A through E) differ in genome, transmission, chronicity risk, and oncogenic potential: HAV and HEV are fecal-oral, self-limited infections, while HBV, HCV, and HDV are parenterally transmitted with significant potential for chronicity and progression to cirrhosis and hepatocellular carcinoma.

Key diagnostic principles include the R ratio for classifying the pattern of liver injury (hepatocellular vs. cholestatic vs. mixed) and systematic interpretation of hepatitis B serologies (HBsAg, anti-HBs, anti-HBc IgM/IgG, HBeAg, anti-HBe) to determine infection status and phase. The distinction between acute and chronic hepatitis has profound therapeutic implications: acute hepatitis is usually self-limited and managed supportively, whereas chronic hepatitis requires disease-specific therapy (DAAs for HCV, nucleos(t)ide analogues for HBV, immunosuppression for AIH) aimed at halting or reversing fibrosis progression. Emerging research highlights the reversibility of fibrosis with successful etiologic treatment and the molecular mechanisms of hepatocarcinogenesis, including HBV DNA integration and HBx-mediated p53 inactivation—concepts that bridge foundational hepatitis pathophysiology to the frontiers of hepatology and oncology.